COSMO Pharmaceuticals N.V. (COPN) AI Stock Analysis

• Market Cap: CHF1.28B
• Dividend Yield: 1.82%
• Average Volume (3M): 19.52K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.07
• Revenue Growth: -3.44%
• EPS Growth: -21.64%
• Country: CH
• Employees: 321
• Sector: General
• Sector Strength: N/A
• Industry: Drug Manufacturers - General
• EPS (TTM): -0.02
• Shares Outstanding: 17,543,522
• 10 Day Avg. Volume: 18,700
• 30 Day Avg. Volume: 19,520
• PEG Ratio: 4.83
• Price to Book (P/B): 3.74
• Price to Sales (P/S): 17.21
• P/FCF Ratio: -113.83
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF140.00
• Price Target Upside: 84.70% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): 0.74
• Revenue Forecast (FY): CHF127.47M

• Rating: 49 Neutral
• Price Target: CHF75.00 ▼(-1.06% Downside)
• Action: Reiterated Date: 03/12/26
• Date: Action: Reiterated 03/12/26

The score is driven primarily by unstable operating results and a sharp 2025 deterioration in profitability and cash generation, despite a very strong, low-leverage balance sheet. Weak technical momentum adds near-term risk, while valuation is constrained by negative earnings with only modest support from the ~2% dividend yield.

Positive Factors

Conservative balance sheet

Very low leverage (debt-to-equity ~0.4%–0.9%) and substantial equity (~482M in 2025) give Cosmo a durable financial cushion. This allows the company to fund R&D, absorb operational shocks, pursue licensing deals or opportunistic M&A, and avoid urgent refinancing in down cycles.

Specialized gastroenterology franchise

A focused product and technology set for gastroenterology and endoscopy builds lasting competitive advantages: deeper clinical relationships, specialized sales channels, and recurring demand from endoscopy centers. Specialization supports repeatable product adoption and targeted commercial execution.

Demonstrated high-margin potential

The exceptional 2024 performance shows the business can achieve very high margins and strong cash conversion when commercial and licensing dynamics align. This proves scalable economics exist, enabling self-funding of growth and R&D in years with successful product cycles or partner milestones.

Negative Factors

Revenue and profit volatility

A ~42% revenue decline and swing to negative margins in 2025 underline structural volatility in demand or execution. Such swings reduce visibility into sustainable earnings, complicate investment and hiring decisions, and make it harder to demonstrate consistent unit economics to partners and customers.

Negative cash generation in latest year

Cash generation swung from strong positive in 2024 to negative in 2025. Prolonged cash burn would force reliance on reserves or external funding, limit organic investment in launches and R&D, and raise execution risk despite a strong balance sheet if losses persist.

Lumpy licensing/partnership revenue

Significant revenue from upfronts, milestones and royalties creates inherent lumpiness and binary outcomes tied to partner progress and regulatory events. This structure amplifies year-to-year swings, reduces predictability of recurring revenue, and increases reliance on successful partner execution.

COSMO Pharmaceuticals N.V. Business Overview & Revenue Model

Company Description

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

How the Company Makes Money

Cosmo Pharmaceuticals makes money primarily through a mix of (1) sales of its own products where it commercializes directly and/or via distribution arrangements, and (2) partnering economics from out-licensing its products/technologies to other pharmaceutical companies. In licensing and collaboration arrangements, revenue can be generated through upfront payments (paid when a partner obtains rights to develop and/or commercialize a product in certain territories), milestone payments (triggered by achievement of clinical, regulatory, or commercial objectives), and royalties (a percentage of a partner’s net sales after launch). Where Cosmo or its partners commercialize products, revenue is also driven by demand from clinicians and healthcare providers, pricing and reimbursement dynamics in target markets, and the breadth and effectiveness of commercial distribution. Specific material partnerships, product-level contributions, and the split between direct product sales versus licensing/royalty income are not available in the prompt and are therefore null.

COSMO Pharmaceuticals N.V. Financial Statement Overview

Summary

Financials are mixed: a very strong but non-repeatable-looking 2024 was followed by a sharp 2025 downturn (revenue down ~42%, negative net and EBIT margins) and negative operating/free cash flow. The balance sheet is a clear strength with minimal leverage and substantial equity, but earnings and cash-flow volatility materially reduce the score.

Income Statement

Results are highly volatile. After an exceptionally strong 2024 (revenue 266.8M with ~50% net margin), 2025 revenue fell sharply to 104.9M (down ~42%) and profitability turned negative (net margin ~-3.5%, EBIT margin ~-10%). Earlier years also show uneven earnings (losses in 2020 and 2023), suggesting the business can generate strong profits in good years but lacks consistency and visibility in the current run-rate.

Balance Sheet

Balance sheet looks very conservative with minimal leverage in recent years. Total debt is very low versus equity in 2023–2025 (debt-to-equity ~0.4%–0.9%), and equity remains substantial (~482M in 2025). The main weakness is return on equity turning negative in 2025 after being very strong in 2024, indicating that profitability—rather than balance sheet strength—is the current constraint.

Cash Flow

Cash generation deteriorated meaningfully in 2025, with operating cash flow turning negative (-11.6M) and free cash flow also negative (-15.8M) after strong positive cash flow in 2024 (operating cash flow 162.4M; free cash flow 156.8M). This swing raises near-term quality and sustainability questions, as the latest year shows cash burn rather than self-funding operations.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	104.85M	266.79M	92.78M	102.09M	65.07M
Gross Profit	48.78M	246.92M	53.44M	83.33M	49.93M
EBITDA	2.36M	165.71M	19.70M	46.74M	17.81M
Net Income	-3.63M	133.24M	-4.93M	17.23M	21.67M
Balance Sheet
Total Assets	612.16M	646.77M	553.98M	759.59M	805.56M
Cash, Cash Equivalents and Short-Term Investments	122.66M	142.96M	50.27M	240.95M	222.21M
Total Debt	4.26M	2.20M	1.84M	173.60M	169.92M
Total Liabilities	123.36M	141.68M	124.94M	295.80M	292.88M
Stockholders Equity	481.92M	498.33M	422.16M	456.93M	505.28M
Cash Flow
Free Cash Flow	-15.85M	156.76M	18.31M	25.92M	4.11M
Operating Cash Flow	-11.62M	162.41M	22.71M	33.23M	12.61M
Investing Cash Flow	49.85M	-128.88M	42.30M	1.69M	24.86M
Financing Cash Flow	-24.61M	-40.22M	-211.27M	-46.13M	-27.25M

COSMO Pharmaceuticals N.V. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 75.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:COPN, the sentiment is Negative. The current price of 75.8 is below the 20-day moving average (MA) of 100.00, below the 50-day MA of 109.18, and below the 200-day MA of 78.46, indicating a bearish trend. The MACD of -9.28 indicates Positive momentum. The RSI at 16.76 is Positive, neither overbought nor oversold. The STOCH value of 1.77 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:COPN.

COSMO Pharmaceuticals N.V. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ROG	73 Outperform	CHF240.33B	11.94	31.98%	2.94%	4.77%	-11.07%
BSLN	71 Outperform	CHF634.73M	16.63	―	―	58.51%	―
MED	62 Neutral	CHF1.08B	-168.33	―	―	7.29%	-112.70%
KURN	56 Neutral	CHF916.80M	498.59	-7.82%	―	104.01%	33.25%
MEDX	56 Neutral	CHF350.73M	71.61	―	4.54%	-2.42%	-222.68%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
COPN	49 Neutral	CHF1.28B	-496.80	11.46%	1.82%	-3.44%	-21.64%

COSMO Pharmaceuticals N.V. Corporate Events

Cosmo to Showcase Real-Time Medical AI Platforms at NVIDIA GTC 2026

Cosmo Pharmaceuticals will showcase its real-time medical AI capabilities at NVIDIA GTC 2026 in San Jose, highlighting its role in developing AI systems used during clinical procedures. The company will present a session titled “Engineering Medical Grade Platforms for Real Time AI,” led by senior MedTech AI leaders, outlining how its platforms assist physicians with detection, decision-making and workflow optimization.

By emphasizing products like GI Genius and its use of NVIDIA’s accelerated computing technologies, Cosmo aims to demonstrate how medical-grade AI can deliver measurable value in routine care. The appearance at NVIDIA’s flagship AI conference reinforces Cosmo’s commitment to advancing AI in healthcare and strengthens its positioning as a key player at the convergence of medical technology and artificial intelligence.

The most recent analyst rating on (CH:COPN) stock is a Hold with a CHF93.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.

Cosmo Sets April General Meeting with Name Change and Payout on Agenda

Cosmo Pharmaceuticals N.V. has convened its ordinary General Meeting for 10 April 2026 in Amsterdam, where shareholders will review the 2025 financial year and ESG achievements and decide on profit appropriation. The agenda also includes a proposed EUR 2.10 per share distribution from freely available reserves, discharge of the board from liability, approval of the remuneration policy and reappointment of board members for one-year terms.

Shareholders will vote on amending the articles of association to change the company name to Cosmo N.V. and on several authorizations for the board to issue ordinary and preference shares or grant subscription rights. These measures, alongside updated governance and capital authorization proposals, could influence Cosmo’s capital structure, branding and governance framework, with implications for its strategic flexibility and investor returns.

The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF130.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.

Cosmo Pharmaceuticals Lifts Recurring Revenues, Boosts Dividend and Sets Growth Path to 2030

Cosmo Pharmaceuticals reported 2025 revenue of EUR 104.2 million, with recurring revenues rising 15% to EUR 88.1 million and now accounting for 85% of the total, while EBITDA reached EUR 9.5 million, above guidance despite a small operating loss due to non-recurring 2024 milestones. The company highlighted strong growth from GI Genius and Winlevi, a 6% reduction in operating expenses, a cash and investment position of EUR 128.3 million with no financial debt, a proposed dividend of EUR 2.10 per share, and set 2026 guidance for continued double-digit recurring revenue and EBITDA growth alongside progress on its Vision 2030 targets for a larger, more profitable recurring-revenue base.

For 2026, Cosmo is guiding total revenue of EUR 105–110 million, recurring revenues of EUR 98–102 million, and EBITDA of EUR 10.5–13.5 million, supported by further global expansion of GI Genius and Winlevi and focused R&D in MedTech AI and gastroenterology. Management reiterated mid-term ambitions to grow recurring revenues to around EUR 260 million by 2030, or up to EUR 480 million including pipeline products, with a corresponding increase in EBITDA, underlining the strategic importance of recurring platforms and disciplined capital allocation for shareholders and partners.

The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF134.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.

Cosmo teams with Dutch institutions to expand GI Genius AI into Barrett’s esophagus detection

Cosmo Pharmaceuticals has entered a strategic R&D collaboration with Amsterdam UMC and Eindhoven University of Technology to develop and clinically validate an AI-based detection system for early neoplasia in Barrett’s esophagus. The project aims to extend the GI Genius platform from colorectal cancer prevention into upper gastrointestinal indications, addressing a major challenge in early detection during endoscopy.

The partners will pool clinical, imaging, and technical expertise to build one of the most comprehensive curated datasets in Barrett’s esophagus and to train and validate new AI algorithms in specialized centers. Cosmo will oversee industrialization and regulatory pathways for global markets, reinforcing its Vision 2030 strategy and strengthening its position in AI-supported endoscopy by expanding the GI Genius ecosystem to multiple GI diseases.

The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF134.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.

Cosmo Pharmaceuticals to Court Investors at Major 2026 Healthcare Conferences

Cosmo Pharmaceuticals will engage with investors at a series of healthcare and biotech conferences in London, Miami and Paris between March and May 2026. Senior executives, including the CFO and CEO, will hold one-on-one and group meetings, underscoring the company’s efforts to deepen investor relations and raise its profile in the global healthcare investment community.

These appearances are likely to support Cosmo’s positioning as an innovation-focused MedTech and life sciences player by giving management direct access to institutional investors across key markets. The targeted outreach at high-profile sector events may help broaden its shareholder base and strengthen stakeholder confidence in its strategic direction.

The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF134.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.

Cosmo Pharmaceuticals Bolsters Institutional Base With Non‑Dilutive Treasury Share Placement

Cosmo Pharmaceuticals has completed a private placement of 937,086 treasury shares, equivalent to about 5.3% of its outstanding share capital, to SMALLCAP World Fund of Capital Group. Because the transaction used existing treasury shares, it does not dilute current shareholders, while bringing in one of the most significant institutional investments in Cosmo’s recent history. Management positions the deal as a key step in its Vision 2030 strategy, strengthening the company’s shareholder base, enhancing financial flexibility and supporting ongoing investment in its core growth areas of MedTech AI, dermatology, gastroenterology and CDMO, thereby reinforcing its ambition to become a focused, innovation-driven healthcare market leader.

The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF134.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.

Cosmo Pharmaceuticals Sets 9 March 2026 Webcast for 2025 Full-Year Results

Cosmo Pharmaceuticals N.V. will publish its 2025 full-year financial results on 9 March 2026 at 07:00 a.m. CET and will host a live conference call and audio webcast at 10:00 a.m. CET the same day for investors, analysts and journalists. Chief Executive Officer Giovanni Di Napoli and Chief Financial Officer Svetlana Sigalova will present the company’s recent financial and operational performance, outline strategic initiatives, growth opportunities and outlook, and take questions during a Q&A session, with the webcast and presentation to remain accessible online for three months. The company will simultaneously release its 2025 annual report and ESG report on its website, and has flagged key upcoming investor-relations dates on its financial calendar, underscoring its ongoing engagement with the capital markets and broader stakeholder community.

The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF136.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.

Cosmo Pharmaceuticals Enters Scale-Up Phase on Strong 2025 Results and AI, Dermatology Pipeline Momentum

Cosmo Pharmaceuticals reported preliminary 2025 revenues of EUR 104 million, with recurring income driven by GI Genius™ and Winlevi® rising 15% year-on-year to EUR 88 million, and ended the year with more than EUR 128 million in cash and no debt, giving it substantial financial flexibility as it enters a scale-up phase under its Vision 2030 strategy. The company highlighted an operational inflection point with EBITDA at the top end of guidance, the evolution of GI Genius™ into a scalable AI platform including an Apple Vision Pro feasibility study, European regulatory approval for its ColonPRO module, broad international approvals for acne drug Winlevi® ahead of a European launch in 2026, and steady progress in its pipeline for androgenetic alopecia, bile acid diarrhea, distal ulcerative colitis and solid tumors, positioning Cosmo for 2026 value catalysts and potential partnerships that could further strengthen its position in AI-enabled MedTech and dermatology markets.

The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF130.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.